User contributions for Muhammad Waleed

Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽

5 September 2024

18 July 2024

23 May 2024

  • 14:5114:51, 23 May 2024 diff hist +6,189 Glofitamab-gxbmNo edit summary current
  • 14:4014:40, 23 May 2024 diff hist +2,614 N Glofitamab-gxbmCreated page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft..."
  • 14:2214:22, 23 May 2024 diff hist +5,524 Rozanolixizumab-noliNo edit summary current
  • 12:4312:43, 23 May 2024 diff hist +3,235 N Rozanolixizumab-noliCreated page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac..."

16 May 2024

13 May 2024

  • 20:3820:38, 13 May 2024 diff hist +2,766 N Talquetamab-tgvsCreated page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent..."

16 January 2024

27 September 2023

8 September 2023

31 August 2023

10 August 2023

8 August 2023

1 August 2023

16 July 2023

6 July 2023